Upgrade to SI Premium - Free Trial

iBio, Inc. (IBIO)

1.36 -0.04 (2.86%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (9/29/26)

Latest Headlines

Form 10-K iBio, Inc. For: Jun 30 August 28, 2026 8:33 AM - SEC Filing Form 8-K iBio, Inc. For: Aug 28 August 28, 2026 8:31 AM - SEC Filing iBio posts $33M net loss in fiscal 2026 as R&D spending surges August 28, 2026 7:02 AM - StreetInsider iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update August 28, 2026 7:00 AM - StreetInsider Form PRE 14A iBio, Inc. For: Oct 14 August 20, 2026 6:59 AM - SEC Filing Form SCHEDULE 13G iBio, Inc. Filed by: Lynx1 Capital Management LP August 14, 2026 4:41 PM - SEC Filing Form SCHEDULE 13G/A iBio, Inc. Filed by: Vestal Point Capital, LP August 14, 2026 4:11 PM - SEC Filing Form SCHEDULE 13G/A iBio, Inc. Filed by: Cormorant Asset Management, LP August 14, 2026 2:04 PM - SEC Filing Form SCHEDULE 13G/A iBio, Inc. Filed by: Affinity Asset Advisors, LLC August 13, 2026 4:08 PM - SEC Filing Form 4 iBio, Inc. For: Jul 31 Filed by: Carr Molly August 4, 2026 4:02 PM - SEC Filing Form 3 iBio, Inc. For: Jul 31 Filed by: Carr Molly August 4, 2026 7:16 AM - SEC Filing Form 8-K iBio, Inc. For: Jul 31 August 4, 2026 7:06 AM - SEC Filing iBio names endocrinologist Molly Carr as chief medical officer August 4, 2026 7:00 AM - StreetInsider iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer August 4, 2026 7:00 AM - StreetInsider Form 8-K iBio, Inc. For: Jul 17 July 17, 2026 4:09 PM - SEC Filing Form 8-K iBio, Inc. For: Jul 01 July 1, 2026 7:33 AM - SEC Filing iBio reports preclinical data on IBIO-610 Activin E antibody in obese NHPs July 1, 2026 7:02 AM - StreetInsider iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study July 1, 2026 7:00 AM - StreetInsider Raymond James Starts iBio, Inc. (IBIO) at Outperform June 8, 2026 6:07 AM - StreetInsider B.Riley Starts iBio, Inc. (IBIO) at Buy June 5, 2026 8:36 AM - StreetInsider iBio to Participate in Upcoming Healthcare Investor Conferences June 2, 2026 4:01 PM - StreetInsider iBio begins phase 1 trial of obesity drug IBIO-600 June 2, 2026 7:00 AM - StreetInsider iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity June 2, 2026 7:00 AM - StreetInsider Full Article List